LivaNova’s Strong Q1 2025 Performance and Positive Outlook Justify Buy Rating

Analyst Michael Matson from Needham reiterated a Buy rating on LivaNova (LIVN – Research Report) and keeping the price target at $64.00.

Michael Matson has given his Buy rating due to a combination of factors including LivaNova’s strong financial performance in the first quarter of 2025. The company exceeded expectations in both revenue and earnings per share, with organic revenue growth accelerating significantly compared to the previous quarter.
Additionally, despite slight adjustments to the 2025 earnings guidance to account for interest on the Italian liability and tariffs, the impact was less severe than anticipated. The Cardiopulmonary business outperformed expectations, and the Neuromodulation segment showed improved growth. Furthermore, positive trial results and regulatory progress with the FDA support a positive outlook. With these developments and the resolution of key uncertainties, Matson maintains a Buy rating on LivaNova’s stock.